Phase II triple-negative breast cancer trial restarts
Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The clinical biotechnology company is focused on the discovery and development of novel intratumoural cancer therapies that are designed to kill tumours and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology. The trial (NCT06358573) analyses… Read More
